Galena Biopharma (SLS) Upgraded to Buy: What Does It Mean for the Stock?Zacks Investment Research • 06/23/25
SELLAS Life Sciences Expands Scientific Advisory Board with Addition of Two World-Renowned Hematology and Oncology ExpertsGlobeNewsWire • 06/05/25
SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual MeetingGlobeNewsWire • 06/02/25
SELLAS Life Sciences to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company ShowcaseGlobeNewsWire • 05/20/25
SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AMLGlobeNewsWire • 05/15/25
SELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/13/25
SELLAS Unveils Breakthrough Preclinical Data Highlighting Efficacy of SLS009 in TP53 Mutated AML at the 2025 AACR ConferenceGlobeNewsWire • 04/28/25
SELLAS to Present at the 2025 American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewsWire • 04/23/25
SELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AMLGlobeNewsWire • 04/08/25
Sellas Life Sciences: A Hold For Now With Huge, But Uncertain, Near-Term CatalystSeeking Alpha • 03/31/25
SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate UpdateGlobeNewsWire • 03/20/25
SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCLGlobeNewsWire • 02/20/25
SELLAS Life Sciences Group Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesGlobeNewsWire • 01/28/25
SELLAS Life Sciences Announces Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of GPS in Acute Myeloid LeukemiaGlobeNewsWire • 01/23/25
SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid LeukemiaGlobeNewsWire • 12/10/24
SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 in r/r AMLGlobeNewsWire • 12/09/24
SELLAS Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor of Response to SLS009 in Solid CancersGlobeNewsWire • 11/27/24
SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/13/24
voxeljet, Dressler Group GmbH, Fraunhofer IPA and the University of Bayreuth Collaborate in Re-Processing of Discarded PA12 Powder for 3D Printing via High-Speed Sintering (HSS)Business Wire • 11/13/24
SELLAS Life Sciences to Present at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition 2024GlobeNewsWire • 11/05/24
SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S (GPS) for the Treatment of Pediatric Acute Myeloid LeukemiaGlobeNewsWire • 10/15/24
SELLAS Life Sciences to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual SummitGlobeNewsWire • 10/10/24
SELLAS Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/13/24